Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 2026
Haemonetics (NYSE: HAE) plans to publish its second-quarter fiscal year 2027 financial results on November 5, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Haemonetics (NYSE: HAE) plans to publish its second-quarter fiscal year 2027 financial results on November 5, 2026. Results are scheduled for 6:00 am ET, followed by an investor and analyst conference call at 8:00 am ET to discuss results and answer questions. A live webcast will be available on the company's investor relations website. A replay will be available for one year beginning November 5, 2026, at 11:00 am ET.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The call can be accessed via teleconference at: Q2 2027 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.
A live webcast of the call can be accessed on Haemonetics' investor relations website. Webcast Link: https://edge.media-server.com/mmc/p/kf8g7up6
A replay of the conference call and webcast will be available for one year beginning on November 5, 2026 at 11:00 am ET using the conference call webcast link provided in this press release.
ABOUT HAEMONETICS
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our Apheresis business features proprietary technologies designed to enhance safety, yield, donor satisfaction and operational efficiency for plasma and blood collectors around the world. Our MedSurg business offers Blood Management Technologies to help inform treatment decisions and optimize the management of blood products, and Interventional Technologies, including advanced vascular closure systems and sensor-guided technologies, designed to drive procedural effectiveness and elevate the patient experience. To learn more about Haemonetics, visit www.haemonetics.com.
|
Investor Contacts: |
|
|
Olga Guyette, Vice President-Investor Relations & Treasury |
David Trenk, Sr. Manager-Investor Relations |
|
(781) 356-9763 |
(203) 733-4987 |
|
|
|
|
Media Contact: |
|
|
Josh Gitelson, Sr. Director-Global Communications |
|
|
(781) 356-9776 |
|
|
|
View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-sets-date-for-publishing-second-quarter-fiscal-year-2027-results-november-5-2026-302894803.html
SOURCE Haemonetics Corporation